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The Indiana State Department of Health (ISDH) and the Centers for Disease Control and Prevention 
(CDC) are investigating a large outbreak of recent human immunodeficiency virus (HIV) infections among 
persons who inject drugs (PWID). Many of the HIV-infected individuals in this outbreak are co-infected 
with hepatitis C virus (HCV). The purpose of this HAN Advisory is to alert public health departments and 
healthcare providers of the possibility of HIV outbreaks among PWID and to provide guidance to assist in 




From November 2014 to January 2015, ISDH identified 11 new HIV infections in a rural southeastern 
county where fewer than 5 infections have been identified annually in the past. As of April 21, 2015, an 
on-going investigation by ISDH with assistance from CDC has identified 135 persons with newly 
diagnosed HIV infections in a community of 4,200 people; 84% were also HCV infected. Among 112 
persons interviewed thus far, 108 (96%) injected drugs; all reported dissolving and injecting tablets of the 
prescription-type opioid oxymorphone (OPANA® ER) using shared drug preparation and injection 
equipment.1 
 
This HIV outbreak was first recognized by a local disease intervention specialist. In late 2014, interviews 
conducted with three persons newly diagnosed with HIV infections in three separate venues (i.e., an 
outpatient clinic, a drug rehabilitation program, during a hospitalization) indicated that two of these 
persons had recently injected drugs and had numerous syringe-sharing and sexual partners. Contact 
tracing identified eight additional HIV infections leading to the current outbreak investigation, which has 
demonstrated that HIV had spread recently and rapidly through the local network of PWID. Without an 
attentive health department, active case finding, and additional testing provided as part of this 
investigation, this cluster may not have been identified.  
 
Urgent action is needed to prevent further HIV and HCV transmission in this area and to investigate and 
control any similar outbreaks in other communities.  
 
Injection drug use accounts for an estimated 8%2 of the approximate 50,000 annual new HIV infections in 
the United States.3  HCV infection is the most common blood-borne infection in the United States and 
percutaneous exposure via drug-injecting equipment contaminated with HCV-infected blood is the most 
frequent mode of transmission. Nationally, acute HCV infections have increased 150% from 2010 to 
2013,4 and over 70% of long-term PWID may be infected with HCV.5  Abuse of prescription-type opioids 
is increasing nationally6 and opioid-analgesic poisoning deaths have nearly quadrupled from 1999 
through 2011.7  Rates of acute HCV infection are increasing, especially among young nonurban PWID, 
often in association with abuse of injected prescription-type opioids. These increases have been most 
substantial in nonurban counties east of the Mississippi River.8   
Recommendations for Health Departments  
 Review the most recent sources of data on HIV diagnoses, HCV diagnoses (acute as well as past 
or present), overdose deaths, admissions for drug treatment, and drug arrests. Attributes of 
communities at risk for unrecognized clusters of HIV and HCV infection include the following: 
o Recent increases in the: 
 Number of HIV infections attributed to injection drug use, 
 Number of HCV infections, particularly among persons aged < 35 years; 
o High rates of injection drug use and especially prescription-type opioid abuse, drug-
related overdose, drug treatment admission, or drug arrests. 
 Ensure complete contact tracing for all new HIV diagnoses and testing of all contacts for HIV and 
HCV infection. 
 Ensure persons actively injecting drugs or at high-risk of drug injection (e.g., participating in drug 
substitution programs, receiving substance abuse counseling or treatment, recently or currently 
incarcerated) have access to integrated prevention services,9 and specifically:  
o Are tested regularly for HIV and HCV infection (consider more frequent testing based 
on frequency of injection drug usage or sharing of injection equipment); 
o If diagnosed with HIV or HCV infection: 
 Are rapidly linked to care and treatment services; 
o If actively injecting drugs: 
 Have access to medication-assisted therapy (e.g., opioid substitution therapy) 
as well as other substance abuse services, if not already engaged, 
 Are counseled not to share needles and syringes or drug preparation 
equipment (e.g., cookers, water, filters),  
 Have access to sterile injection equipment from a reliable source. 
o If not HIV infected but actively injecting drugs: 
 Are referred for consideration of HIV pre-exposure prophylaxis10 and if 
potentially exposed within the past 72 hours (e.g., shared drug preparation or 
injection equipment with a known or potentially HIV-infected person) HIV post-
exposure prophylaxis11,12  
 Remind venues that may encounter unrecognized infections, such as emergency departments 
and community-based clinical practices (e.g., family medicine, general medicine, prenatal care) of 
the importance of routine opt-out HIV testing as well as HCV testing per current 
recommendations13-15 
 Local health departments should notify their state health department and CDC of any suspected 
clusters of recent HIV or HCV infection. 
Recommendations for Healthcare Providers 
 Ensure all persons diagnosed with HCV infection are tested for HIV infection,16 and that all 
persons diagnosed with HIV infection are tested for HCV infection.17 
 Ensure persons receiving treatment for HIV and/or HCV infection adhere to prescribed therapy 
and are engaged in ongoing care. 
 Encourage HIV and HCV testing of syringe-sharing and sexual partners of persons diagnosed 
with either infection. 
 Report all newly diagnosed HIV and HCV infections to the health department.  
 For all persons with substance abuse problems: 
o Refer them for medication-assisted treatment (e.g., opioid substitution therapy) and 
counseling services, 
o Use effective treatments (e.g., methadone, buprenorphine), as appropriately indicated.  
 For any persons for whom opioids are under consideration for pain management: 
o Discuss the risks and benefits of all pain treatment options, including ones that do not 
involve prescription analgesics.  
o Note that long-term opioid therapy has not been demonstrated to reduce chronic pain.18 
 Contact the state or local health department to report suspected clusters of recent HIV or HCV 
infection. 
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The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and injuries; enhances health decisions by providing credible information on critical health 





Categories of Health Alert Network messages:  
Health Alert  Requires immediate action or attention; highest level of importance 
Health Advisory May not require immediate action; provides important information for a specific incident or situation 
Health Update   Unlikely to require immediate action; provides updated information regarding an incident or situation 
HAN Info Service Does not require immediate action; provides general public health information 
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